Contact

Spanish biotechs go public


,
Integral service around a transaction
BY : Diego GutiérrezNovember Thu, 2015
It is not uncommon for the biotech sector to be punished on occasion in the stock market because of traditional bubbles and high valuations. However, the S&P Biotechnology select Industry index shows that the situation has improved and has risen by 11% since January. In addition, of the 200 or so biotechs listed on Wall Street, none of them have a sell recommendation.. Moreover, experts are betting to buy or overweight around 190 of them. Spanish companies are also taking the plunge and Neol Bio has recently been floated on the MAB, while Oryzon's IPO is imminent and is set to take place before Christmas.

AUTOTAGGING - feasibility plan- 2015-10 (8)
 
 

Neol Bio goes public on the MAB

Neol Bio, dedicated to the development of innovative microbial industrial biotechnology processes, debuted on the Alternative Stock Market (MAB) at the end of November.

The president of Neol Bio, José Manuel Arrojo, said that joining the MAB provides the company with "financing channels to guarantee the growth of the company for the new phase of development in which it finds itself, thanks to the notoriety that this market provides and the transparency and rigour that it demands". The sectors in which we operate; Oleochemicals, Omega-3 DHA and Bioenergy, and the technologies we develop will allow us, with the right financing, to multiply the size and value of Neol Bio several times over".

Oryzon is in the final stages of its IPO

Oryzonwhich researches diseases such as leukaemia and Alzheimer's, wants to go public before Christmas, although it says it does not rule out delays. The company's valuation will be €96M and a price per share of €3.39.

"As we already communicated in a previous post, Oryzon has recently received a €16.5M round to prepare for the IPO" says Diego Gutierrez of Oryzon. Abra-Invest.

In addition, the company sees the IPO as a stepping stone to the American market.

Oryzon achieved a net profit of €6.6 million in 2014, with record revenues of €13.1 million after signing its first licensing agreement with multinational Roche for €$21M and development milestones of up to €500M for its OLY1001 molecule for acute myeloid leukaemia.

Transplant biomedical raises €1.5M

Transplant biomedical has closed a €1.5M round which was led by Kereon Partners, and in which he has also participated Caixa Capital Risc.

The Barcelona-based company is developing an innovative medical device for the preservation and transport of abdominal and thoracic organs for transplantation. The funds raised in the round will be used to accelerate the development and commercialisation of this device.

The company intends to start marketing the system between 2017 and 2018.

 "This device would improve post-transplant outcomes and lead to a better use of available organs and therefore to a reduction in the mortality of patients awaiting transplantation, as it would maintain the abdominal organs in better condition than at present during transport (cold ischaemia), thus increasing the viability of such grafts prior to transplantation.e"says Dr Joan Rodés, president of the Institut d'Investigacions Biomèdiques Agustí Pi i Sunyer (IDIBAPS) and member of the company's Scientific Advisory Board.

If you are looking for funding, please contact us. Abra-Invest has an expert team in alternative financing at your disposal with many years of experience in the biotech sector. Fill in the contact form or call us on + 34 946424142

Other posts that may interest you

October 2015: Funding for the biotech sector: InnoUp Farma and Oryzon Genomics  Spanish biotechs go international: Artax Biopharma, PharmaMar and Mind The Byte.

 

The M&A Professionals

Meet our services

MEET
OUR
METODOLOGY

Do you want to be up to date?

SUSCRIBE OUR NEWSLETTER

Our diferentiation

Market Research Technology
Our team of market analysis specialists is continuously analyzing the investments of the most active markets in the industry in order to unceasingly contribute ideas of the current market situation and identify the most relevant trends for senior management. We integrate the most relevant sources of information which allows us to discover the most interesting companies for venture capital and similarly helps us to identify the investors with the highest probability of involvement in an M&A process to ensure the success of our sell-side operations.

The reports and deductions of our advisors provide a broad view of the sector, both geographically and from the complementary or adjacent markets perspective.
Technology Data Analytics
for M&A
Advanced data anlytics is a weapon". Intelfin is an artificial intelligence tool we use for investing and creating value in SMEs through competitive analytics and the enterprise environment.

IntelFin consists of a cognitive system, which, through the application of advanced analytical technologies, facilitates the automation of investment and financing decisions in the field of non-listed companies and especially SMEs in high-growth sectors.

The information related to these companies is characterized by their lack of transparency and heterogeneity; thus, it is necessary to develop an advanced analysis which is as much predictive as prescriptive and is developed in a natural language custom, suitable to obtain greater clarity and knowledge of the investment scope.

The IntelFin system focuses especially on analyzing the variables that define and influence the competitive environment of a sector and the positioning of a company, analyzing their influence on future value creation. Therefore, IntelFin supports strategic decision-making to senior management by resolving questions such as:

¿What are my competitors' priorities, strategies and expansion plans? Who's my competition? Which competitor is most likely to grow at a higher rate?
Which areas of activity/business models will receive the most investment? Which sectors are most attractive to investors?
Which companies are going to experience the most growth in the near future? Which companies are most likely to receive investment or be acquired?
Training Methodology
We have developed training programs in an innovative set-up which guarantees our teams the acquisition of technical competences both in the field of corporate finance and in the field of psychology, that is much needed when it comes to negotiation processes.

We have a culture of continuous improvement of our processes, closely related to the use of information systems that allow the enhancement of internal communication between our teams, as well as external communication with our customers. Hence, we extend best practices identified internally in an efficient and rapid manner among our members.

Are you one of those who prefer to be well informed when making decisions?

M&A NEWS
INDUSTRIAL REPORTS
closearrow-circle-o-downchevron-downcrossmenu